These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28578773)

  • 21. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent legislation changes the economics of cancer care.
    Silberman G; Downs CG
    ONS News; 2005 Jul; 20(7):9. PubMed ID: 16045235
    [No Abstract]   [Full Text] [Related]  

  • 24. L'évaluation d'impact sur la santé en Montérégie : un processus appuyé sur le courtage de connaissances.
    Tremblay É; St-Pierre L; Viens C
    Glob Health Promot; 2017 Jun; 24(2):66-74. PubMed ID: 28492098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
    Martin T; Rioufol C; Favier B; Martelli N; Madelaine I; Chouaid C; Borget I
    BioDrugs; 2024 May; 38(3):465-475. PubMed ID: 38643301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value and payment for oncology in the United States.
    Robinson JC
    Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The long battle over payment for oncology services in the office setting.
    Bailes JS; Coleman TS
    J Oncol Pract; 2014 Jan; 10(1):1-4. PubMed ID: 24443726
    [No Abstract]   [Full Text] [Related]  

  • 28. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 29. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 30. New Challenges in Oncology for the Brazilian Private Health Sector: Specialists' Concerns After the ISPOR International Congress in Boston, Massachusetts, 2017.
    Santos M; Stefani S; Neto JPR; Santos MC
    Value Health Reg Issues; 2019 Dec; 20():12-18. PubMed ID: 30634086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.
    J Natl Cancer Inst Monogr; 1998; (24):1-28. PubMed ID: 9704318
    [No Abstract]   [Full Text] [Related]  

  • 32. An Oncologist's Letter to Santa.
    Tempero M
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1491. PubMed ID: 27956532
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cancer and health economics].
    Koinuma N
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):1-7. PubMed ID: 8546457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How Long Should We Continue the Chemotherapy?-From the View Point of Health Economics].
    Koinuma N
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):809-18. PubMed ID: 27431625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.
    Vermaelen K; Waeytens A; Kholmanskikh O; Van den Bulcke M; Van Valckenborgh E
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):166-177. PubMed ID: 29170067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic aspects of cancer care.
    Maynard A
    Eur J Cancer; 1993; 29A Suppl 7():S6-9. PubMed ID: 8312062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus canadien sur la nutrition féminine : adolescence, reproduction, ménopause et au-delà.
    ; O'Connor DL; Blake J; Bell R; Bowen A; Callum J; Fenton S; Gray-Donald K; Rossiter M; Adamo K; Brett K; Khatri N; Robinson N; Tumback L; Cheung A
    J Obstet Gynaecol Can; 2016 Jun; 38(6):555-609.e19. PubMed ID: 27368136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
    Franken MG; van Gils CW; Gaultney JG; Delwel GO; Goettsch W; Huijgens PC; Steenhoek A; Punt CJ; Koopman M; Redekop WK; Uyl-de Groot CA
    Eur J Cancer; 2013 Jan; 49(1):8-16. PubMed ID: 22809557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPIKE$: a six-step protocol for delivering bad news about the cost of medical care.
    McFarlane J; Riggins J; Smith TJ
    J Clin Oncol; 2008 Sep; 26(25):4200-4. PubMed ID: 18757335
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.